Understanding how Ponatinib causes vascular damage
Official title: Mechanism of Ponatinib induced vascular toxicity
Funded at Tufts University Boston · NIH-10900243 · Data updated 2026-11-12
This study is looking into how the cancer drug Ponatinib, used for treating chronic myelogenous leukemia, might increase the risk of heart problems and strokes, so we can find safer treatment options for patients like you.
Quick facts
| Grant type | Fellowship grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Tufts University Boston NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project start | September 16, 2024 |
| Project end | September 15, 2026 |
| Funding year | 2024 |
| Award (this year) | $44,724 |
| NIH project number | 1F30HL170641-01A1 |
| Project ID | NIH-10900243 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients with chronic myelogenous leukemia who are being treated with Ponatinib and have pre-existing cardiovascular risk factors.
✕Less likely to help
Patients who do not have chronic myelogenous leukemia or those who are not receiving Ponatinib may not benefit from this research.
What this research studies
This research investigates the harmful effects of Ponatinib, a medication used to treat chronic myelogenous leukemia (CML), particularly its association with increased risks of serious cardiovascular events like heart attacks and strokes. The study aims to uncover the mechanisms behind this vascular toxicity by examining how Ponatinib may inflame existing atherosclerotic plaques in patients. By analyzing the behavior of endothelial cells and the role of inflammatory cytokines, the research seeks to provide insights that could lead to safer treatment options for CML patients. The findings could help improve patient outcomes by addressing the cardiovascular risks associated with this therapy.
Why it matters
Potential benefit: If successful, this research could lead to safer treatment strategies for CML patients, reducing the risk of life-threatening cardiovascular events.
How similar studies have gone: While there have been studies on the effects of other Abl-tyrosine kinase inhibitors, the specific mechanisms of Ponatinib-induced vascular toxicity are still being explored, making this research a novel investigation.
Where this research is happening
-
Tufts University Boston
Boston, United States Active
Researchers
- Principal investigator: Stepanian, Alec — Tufts University Boston
- Study coordinator: Stepanian, Alec
Related research
Other NIH-funded projects on the same topics.
-
Diagnostics Core for Lyme disease testing and sample archiving
A centralized diagnostics core at a CLIA-certified lab provides standard Lyme disease tests and sample handling to support patient studies.
-
Clinical Coordination Core for Lyme disease and tickborne infections
A patient-facing core is coordinating care and enrollment for people with early Lyme disease and for antibody-based studies among groups at high risk of tick exposure.
-
Understanding why some people have ongoing symptoms after Lyme disease
A long-term study follows people diagnosed with acute Lyme disease to see who develops persistent symptoms and why, with care from a team of Lyme experts.
-
How bacteria talk to each other and what that means for infections
Researchers are studying how bacteria communicate and adapt in crowded environments like infections, with the goal of understanding what makes some bacteria more harmful or harder to treat.
-
Transdiagnostic therapy to improve mental health and TB treatment outcomes in India
A doctor-research team will test a flexible mental health therapy called CETA to help people with tuberculosis who also struggle with depression and unhealthy alcohol use, aiming to improve their TB treatment success.
-
Precision nutrition for personalized health in All of Us New England
A patient-focused program will study how different diets affect health in adults in the All of Us community, using real-world meals and controlled feeding sessions.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.